Cytopenias in pediatric kidney transplant recipients: preceding factors and clinical consequences.
Children
Kidney transplantation
Neutropenia
Rejection
Thrombocytopenia
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
15
10
2022
accepted:
01
02
2023
revised:
30
01
2023
medline:
31
8
2023
pubmed:
20
4
2023
entrez:
20
04
2023
Statut:
ppublish
Résumé
Kidney trans plantation is associated with secondary complications, including the risk of developing posttransplant cytopenias. This study aimed to evaluate the characteristics, identify predictors, and assess the management and consequences of cytopenias in the pediatric kidney transplant population. This is a single-center retrospective analysis of 89 pediatric kidney transplant recipients. Possible factors preceding cytopenias were compared with the goal of recognizing predictors for posttransplant cytopenias. Posttransplant neutropenias were analyzed for the total study period and separately for the period beyond 6 months posttransplant (late neutropenias), to rule out confounding influences of induction and initial intensive therapy. Sixty patients (67%) developed at least one episode of posttransplant cytopenia. All episodes of posttransplant thrombocytopenias were mild or moderate. Posttransplant infections and graft rejection were found to be significant predictors for thrombocytopenia (HR 6.06, 95% CI 1.6-22.9, and HR 5.82, 95% CI 1.27-26.6, respectively). A total of 30% of posttransplant neutropenias were severe (ANC ≤ 500). Pretransplant dialysis and posttransplant infections were significant predictors for late neutropenias (HR 11.2, 95% CI 1.45-86.4, and HR 3.32, 95% CI 1.46-7.57, respectively). Graft rejection occurred in 10% of patients with cytopenia, all following neutropenia, within 3 months from cytopenia appearance. In all such cases, mycophenolate mofetil dosing had been held or reduced prior to rejection. Posttransplant infections are substantial contributors to developing posttransplant cytopenias. Preemptive transplantation appears to reduce risk of late neutropenia, the accompanying reduction in immunosuppressive therapy, and the ensuing risk of graft rejection. An alternative response to neutropenia, possibly using granulocyte colony stimulating factor, may diminish graft rejection. A higher resolution version of the Graphical abstract is available as Supplementary information.
Sections du résumé
BACKGROUND
Kidney trans plantation is associated with secondary complications, including the risk of developing posttransplant cytopenias. This study aimed to evaluate the characteristics, identify predictors, and assess the management and consequences of cytopenias in the pediatric kidney transplant population.
METHODS
This is a single-center retrospective analysis of 89 pediatric kidney transplant recipients. Possible factors preceding cytopenias were compared with the goal of recognizing predictors for posttransplant cytopenias. Posttransplant neutropenias were analyzed for the total study period and separately for the period beyond 6 months posttransplant (late neutropenias), to rule out confounding influences of induction and initial intensive therapy.
RESULTS
Sixty patients (67%) developed at least one episode of posttransplant cytopenia. All episodes of posttransplant thrombocytopenias were mild or moderate. Posttransplant infections and graft rejection were found to be significant predictors for thrombocytopenia (HR 6.06, 95% CI 1.6-22.9, and HR 5.82, 95% CI 1.27-26.6, respectively). A total of 30% of posttransplant neutropenias were severe (ANC ≤ 500). Pretransplant dialysis and posttransplant infections were significant predictors for late neutropenias (HR 11.2, 95% CI 1.45-86.4, and HR 3.32, 95% CI 1.46-7.57, respectively). Graft rejection occurred in 10% of patients with cytopenia, all following neutropenia, within 3 months from cytopenia appearance. In all such cases, mycophenolate mofetil dosing had been held or reduced prior to rejection.
CONCLUSIONS
Posttransplant infections are substantial contributors to developing posttransplant cytopenias. Preemptive transplantation appears to reduce risk of late neutropenia, the accompanying reduction in immunosuppressive therapy, and the ensuing risk of graft rejection. An alternative response to neutropenia, possibly using granulocyte colony stimulating factor, may diminish graft rejection. A higher resolution version of the Graphical abstract is available as Supplementary information.
Identifiants
pubmed: 37079102
doi: 10.1007/s00467-023-05905-1
pii: 10.1007/s00467-023-05905-1
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3445-3454Informations de copyright
© 2023. The Author(s), under exclusive licence to International Pediatric Nephrology Association.
Références
Dharnidharka VR, Fiorina P, Harmon WE (2014) Kidney transplantation in children. N Engl J Med 371:549–558. https://doi.org/10.1056/NEJMra1314376
doi: 10.1056/NEJMra1314376
pubmed: 25099579
Davidovits M, Reisman L, Cleper R, Bar-Nathan N, Krause I, Dagan A, Zanhendler N, Chodick G, Hocherman O, Mor M, Aisner S, Mor E (2021) Long-term outcomes during 37 years of pediatric kidney transplantation: a cohort study comparing ethnic groups. Pediat Nephrol 36:1881–1888. https://doi.org/10.1007/s00467-020-04908-6
doi: 10.1007/s00467-020-04908-6
pubmed: 33459932
Saeed B (2012) Pediatric renal transplantation. Int J Organ Transplant Med 3:62–73
pubmed: 25013625
pmcid: 4089282
Sacca E, Hazza I (2003) Pre-emptive pediatric renal transplantation. Saudi J Kidney Dis Transplant 14:442–450
McDonald SP, Craig JC (2004) Long-term survival of children with end-stage renal disease. N Engl J Med 350:2654–2662. https://doi.org/10.1056/NEJMoa031643
doi: 10.1056/NEJMoa031643
pubmed: 15215481
Van Arendonk KJ, Boyarsky BJ, Orandi BJ, James NT, Smith JM, Colombani PM, Segev DL (2014) National trends over 25 years in pediatric kidney transplant outcomes. Pediatrics 133:594–601. https://doi.org/10.1542/peds.2013-2775
doi: 10.1542/peds.2013-2775
pubmed: 24616363
pmcid: 4530294
Zaza G, Tomei P, Granata S, Boschiero L, Lupo A (2014) Monoclonal antibody therapy and renal transplantation: focus on adverse effects. Toxins 6:869–891. https://doi.org/10.3390/toxins6030869
doi: 10.3390/toxins6030869
pubmed: 24590384
pmcid: 3968366
Kuypers DRJ, Claes K, Evenepoel P, Maes B, Vanrenterghem Y (2004) Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 75:434–447. https://doi.org/10.1016/j.clpt.2003.12.009
doi: 10.1016/j.clpt.2003.12.009
pubmed: 15116056
Smith A, Couvillion R, Zhang R, Killackey M, Buell J, Lee B, Saggi BH, Paramesh AS (2014) Incidence and management of leukopenia/neutropenia in 233 kidney transplant patients following single dose alemtuzumab induction. Transplant Proc 46:3400–3404. https://doi.org/10.1016/j.transproceed.2014.07.070
doi: 10.1016/j.transproceed.2014.07.070
pubmed: 25498059
Brum S, Nolasco F, Sousa J, Ferreira A, Possante M, Pinto JR, Barroso E, Santos JR (2008) Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil. Transplant Proc 40:752–754. https://doi.org/10.1016/j.transproceed.2008.02.048
doi: 10.1016/j.transproceed.2008.02.048
pubmed: 18455007
Vinson A, Teixeira A, Kiberd B, Tennankore K (2021) Predictors and complications of post kidney transplant leukopenia. Prog Transplant 31:249–256. https://doi.org/10.1177/15269248211024614
doi: 10.1177/15269248211024614
pubmed: 34159855
Luan FL, Kommareddi M, Ojo AO (2011) Impact of cytomegalovirus disease in D+/R– kidney transplant patients receiving 6 months low-dose valganciclovir prophylaxis. Am J Transplant 11:1936–1942. https://doi.org/10.1111/j.1600-6143.2011.03611.x
doi: 10.1111/j.1600-6143.2011.03611.x
pubmed: 21827608
Keisu M, Wiholm B, Palmblad J (1999) Trimethoprim-sulphamethoxazole-associated blood dyscrasias. ten years’experience of the Swedish spontaneous reporting system. J Intern Med 228:353–360. https://doi.org/10.1111/j.1365-2796.1990.tb00245.x
doi: 10.1111/j.1365-2796.1990.tb00245.x
Golde DW, Bersch N, Quan SG (1978) Trimethoprim and sulphamethoxazole inhibition of haematopoiesis in vitro. Br J Haematol 40:363–367. https://doi.org/10.1111/j.1365-2141.1978.tb05807.x
doi: 10.1111/j.1365-2141.1978.tb05807.x
pubmed: 312108
Smith EP (2010) Hematologic disorders after solid organ transplantation. Hematol 1:281–286. https://doi.org/10.1182/asheducation-2010.1.281
doi: 10.1182/asheducation-2010.1.281
Zafrani L, Truffaut L, Kreis H, Etienne D, Rafat C, Lechaton S, Anglicheau D, Zuber J, Ciroldi M, Thervet E, Snanoudj R, Mamzer MF, Martinez F, Timsit MO, Bergougnoux L, Legendre C (2009) Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. Am J Transplant 9:1816–1825. https://doi.org/10.1111/j.1600-6143.2009.02699.x
doi: 10.1111/j.1600-6143.2009.02699.x
pubmed: 19538494
Yang Y, Yu B, Chen Y (2015) Blood disorders typically associated with renal transplantation. Front Cell Dev Biol 3:18. https://doi.org/10.3389/fcell.2015.00018
doi: 10.3389/fcell.2015.00018
pubmed: 25853131
pmcid: 4365751
Khalil MAM, Khalil MAU, Khan TFT, Tan J (2018) Drug-induced hematological cytopenia in kidney transplantation and the challenges it poses for kidney transplant physicians. J Transplant 2018:9429265. https://doi.org/10.1155/2018/9429265
doi: 10.1155/2018/9429265
pubmed: 30155279
pmcid: 6093016
Xie L, He S, Fu L, Ashok K, Huang Z, Wang L, Lin T (2013) The prevalence and risk factors of thrombocytopenia after living-related renal transplantation in Chinese adult recipients. Transplant Proc 45:197–199. https://doi.org/10.1016/j.transproceed.2012.09.113
doi: 10.1016/j.transproceed.2012.09.113
pubmed: 23375299
Jafari A, Najivash P, Khatami M-R, Dashti-Khavidaki S (2017) Cytopenia occurrence in kidney transplant recipients within early post-transplant period. J Res Pharm Pract 6:31–39. https://doi.org/10.4103/2279-042X.200983
doi: 10.4103/2279-042X.200983
pubmed: 28331864
pmcid: 5348855
Jarasvaraparn C, Choudhury S, Rusch C, Nadler M, Liss KHH, Stoll J, Hmiel S, Khan A, Doyle M, Kulkarni S (2022) Characteristics, risk factors, and outcomes of neutropenia after liver or kidney transplantation in children. Pediatr Transplant 26:14131. https://doi.org/10.1111/petr.14131
doi: 10.1111/petr.14131
Mavrakanas TA, Fournier MA, Clairoux S, Amiel JA, Tremblay ME, Vinh DC, Coursol C, Thirion DJG, Cantarovich M (2017) Neutropenia in kidney and liver transplant recipients: risk factors and outcomes. Clin Transplant 31:(10). https://doi.org/10.1111/ctr.13058
Solez K, Axelsen RA, Benediktsson H, Burdick JF, Cohen AH, Colvin RB, Croker BP, Droz D, Dunnill MS, Halloran PF (1993) International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 44:411–422. https://doi.org/10.1038/ki.1993.259
doi: 10.1038/ki.1993.259
pubmed: 8377384
Mitsnefes MM, Subat-Dezulovic M, Khoury PR, Goebel J, Strife CF (2005) Increasing incidence of post-kidney transplant anemia in children. Am J Transplant 5:1713–1718. https://doi.org/10.1111/j.1600-6143.2005.00919.x
doi: 10.1111/j.1600-6143.2005.00919.x
pubmed: 15943630
Krause I, Davidovits M, Tamary H, Yutcis M, Dagan A (2016) Anemia and markers of erythropoiesis in pediatric kidney transplant recipients compared to children with chronic renal failure. Pediatr Transplant 20:958–962. https://doi.org/10.1111/petr.12792
doi: 10.1111/petr.12792
pubmed: 27620552
Chen G, Gu J, Qiu J, Wang C, Fei J, Deng S, Li J, Huang G, Fu Q, Chen L (2013) Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function. Exp Clin Transplant 11:310–314. https://doi.org/10.6002/ect.2012.0103
doi: 10.6002/ect.2012.0103
pubmed: 23121641
Becker-Cohen R, Ben-Shalom E, Rinat C, Feinstein S, Geylis M, Frishberg Y (2015) Severe neutropenia in children after renal transplantation: incidence, course, and treatment with granulocyte colon-stimulating factor. Pediatr Nephrol 30:2029–2036. https://doi.org/10.1007/s00467-015-3113-7
doi: 10.1007/s00467-015-3113-7
pubmed: 25994524
Hurst FP, Belur P, Nee R, Agodoa LY, Patel P, Abbott KC, Jindal RM (2011) Poor outcomes associated with neutropenia after kidney transplantation: analysis of United States Renal Data System. Transplantation 92:36–40. https://doi.org/10.1097/TP.0b013e31821c1e70
doi: 10.1097/TP.0b013e31821c1e70
pubmed: 21512429
Gupta N, Lawrence RM, Nguyen C, Modica RF (2015) Increased prevalence of polyomavirus BK viruria that correlates with thrombocytopenia in patients with systemic lupus erythematosus on intensive immunosuppressive therapy. Autoimmunity 42:216–223. https://doi.org/10.1080/08916930802709125
doi: 10.1080/08916930802709125
Wang W, Yin H, Li XB, Hu XP, Yang XY, Liu H, Ren L, Wang Y, Zhang XD (2012) A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin. Chin Med J (Engl) 125:1135–1140
pubmed: 22613543
Garcia CD, Bittencourt VB, Rohde RW, Dickel S, Pires I, Tumba K, Vitola SP, de Souza V, Wagner M, Garcia VD (2015) Pre-emptive pediatric kidney transplantation or not? Transplant Proc 47:954–957. https://doi.org/10.1016/j.transproceed.2015.03.019
doi: 10.1016/j.transproceed.2015.03.019
pubmed: 26036493
Bock ME, Cohn RA (2010) Editorial: pre-emptive kidney transplantation - just do it!! Pediatr Transplant 14:561–564. https://doi.org/10.1111/j.1399-3046.2010.01347.x
doi: 10.1111/j.1399-3046.2010.01347.x
pubmed: 20602719
Vats AN, Donaldson L, Fine RN, Chavers BM (2000) Pretransplant dialysis status and outcome of renal transplantation in north american children : a NAPRTCS study North American Pediatric Renal Transplant Cooperative Study. Transplantation 69:1414–1419. https://doi.org/10.1097/00007890-200004150-00035
doi: 10.1097/00007890-200004150-00035
pubmed: 10798764
Cendoroglo M, Jaber BL, Balakrishnan VS, Perianayagam M, King AJ, Pereira BJG (1999) Neutrophil apoptosis and dysfunction in uremia. J Am Soc Nephrol 10:93–100. https://doi.org/10.1681/ASN.V10193
doi: 10.1681/ASN.V10193
pubmed: 9890314
Lemesch S, Ribitsch W, Schilcher G, Spindelböck W, Hafner-Gießauf H, Marsche G, Pasterk L, Payerl D, Schmerböck B, Tawdrous M, Rosenkranz AR, Stiegler P, Kager G, Hallström S, Oettl K, Eberhard K, Horvath A, Leber B, Stadlbauer V (2016) Mode of renal replacement therapy determines endotoxemia and neutrophil dysfunction in chronic kidney disease. Sci Rep 6:34534. https://doi.org/10.1038/srep34534
doi: 10.1038/srep34534
pubmed: 27698480
pmcid: 5048306
Woods GN, Ewing SK, Sigurdsson S, Kado DM, Ix JH, Hue TF, Eiriksdottir G, Xu K, Gudnason V, Lang TF, Vittinghoff E, Harris TB, Rosen CJ, Li X, Schwartz AV (2018) Chronic kidney disease is associated with greater bone marrow adiposity. J Bone Miner 33:2158–2164. https://doi.org/10.1002/jbmr.3562
doi: 10.1002/jbmr.3562
Clayton PA, McDonald SP, Russ GR, Chadban SJ (2019) Long-term outcomes after acute rejection in kidney transplant recipients: an ANZDATA analysis. J Am Soc Nephrol 30:1697–1707. https://doi.org/10.1681/ASN.2018111101
doi: 10.1681/ASN.2018111101
pubmed: 31308074
pmcid: 6727270
Jamil B, Nicholls K, Becker GJ, Walker RG (1999) Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. Transplantation 68:1597–1603. https://doi.org/10.1097/00007890-199911270-00027
doi: 10.1097/00007890-199911270-00027
pubmed: 10589961